NTLA - Intellia Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NTLA is currently covered by 20 analysts with an average price target of $36.55. This is a potential upside of $28.37 (346.82%) from yesterday's end of day stock price of $8.18.

Intellia Therapeutics's activity chart (see below) currently has 182 price targets and 191 ratings on display. The stock rating distribution of NTLA is 28.79% HOLD and 71.21% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 40.88% with an average time for these price targets to be met of 115.69 days.

Highest price target for NTLA is $73, Lowest price target is $9, average price target is $39.21.

Most recent stock forecast was given by BRIAN CHENG from JPMORGAN on 28-Feb-2025.

Currently out of the existing stock ratings of NTLA, 19 are a HOLD (28.79%), 47 are a BUY (71.21%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$13

$5.77 (79.81%)

$55

1 months 28 days ago
(28-Feb-2025)

0/5 (0%)

$2.14 (19.71%)

Buy

$50

$42.77 (591.56%)

1 months 28 days ago
(28-Feb-2025)

1/4 (25%)

$39.14 (360.41%)

3

Hold

$14

$6.77 (93.64%)

$19

1 months 28 days ago
(28-Feb-2025)

3/7 (42.86%)

$3.14 (28.91%)

20

Buy

$68

$60.77 (840.53%)

1 months 28 days ago
(28-Feb-2025)

3/12 (25%)

$57.14 (526.15%)

68

Hold

$9

$1.77 (24.48%)

$76

1 months 28 days ago
(28-Feb-2025)

1/7 (14.29%)

$-1.86 (-17.13%)

20

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NTLA (Intellia Therapeutics) average time for price targets to be met?

On average it took 115.69 days on average for the stock forecasts to be realized with a an average price target met ratio 40.88

Which analyst has the current highest performing score on NTLA (Intellia Therapeutics) with a proven track record?

GEULAH LIVSHITS

Which analyst has the most public recommendations on NTLA (Intellia Therapeutics)?

Geulah Livshits works at CHARDAN CAPITAL and has 9 price targets and 11 ratings on NTLA

Which analyst is the currently most bullish on NTLA (Intellia Therapeutics)?

Swapnil Malekar with highest potential upside - $155.77

Which analyst is the currently most reserved on NTLA (Intellia Therapeutics)?

Martin Auster with lowest potential downside - -$7.62

Intellia Therapeutics in the News

NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against...

Lost Money on Intellia Therapeutics, Inc. (NTLA)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?